Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells’ resistance to anti-tumour drugs

Background and aims: The outcomes of current treatment for non-small cell lung cancer (NSCLC) are unsatisfactory and development of new and more efficacious therapeutic strategies are required. The Notch pathway, which is necessary for cell survival to avert apoptosis, induces the resistance of canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Meng, Jie, Yamin, Li, Ying, Wang, Duo, Li, Man, Li, Dan, E, Mingyan, Li, Yongwu, Liu, Na, Gu, Anxin, Rong, Guanghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338884/
https://www.ncbi.nlm.nih.gov/pubmed/37456760
http://dx.doi.org/10.3389/fphar.2023.1189245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338884/
https://www.ncbi.nlm.nih.gov/pubmed/37456760
http://dx.doi.org/10.3389/fphar.2023.1189245

Ejemplares similares